Table 5.
Dose adjustment of common adverse events of the cmFOLFOXIRI regimen
| Adverse event | Grade | Irinotecan | Oxaliplatin | 5-Fluorouracil |
|---|---|---|---|---|
| Neutropenia | Grade 4 | 80% | 80% | 100% |
| Febrile neutropenia | Grade 3/4 | 80% | 80% | 100% |
| Thrombocytopenia | Grade 3/4 | 80% | 80% | 100% |
| Alanine aminotransferase | Grade 3/4 | 80% | 80% | 100% |
| Aspartate aminotransferase | Grade 3/4 | 80% | 80% | 100% |
| Serum total bilirubin | Grade 3/4 | 80% | 80% | 100% |
| Diarrhea | Grade 3 | 80% | 100% | 80% |
| Diarrhea | Grade 4 | 60% | 100% | 80% |
| Oral mucositis | Grade 3 | 80% | 100% | 80% |
| Oral mucositis | Grade 4 | 80% | 100% | 60% |
| Myocardial infarction | Grade 3/4 | 100% | 100% | STOP |
In the case that the adverse event meets neither the standard of dose reduction nor the standard of administration for the prescribed time of the next cycle, which occurs twice or more repeatedly, following which the decline in the dose. If the dose was reduced twice, the drug should be discontinued. The original dose in this table refers to the dose of the previous chemotherapy, all of which was reduced based on the previous dose.